About SV Health Investors
SV Health Investors offers a healthcare and life sciences venture capital and growth equity firm that makes investments in businesses at all stages of development and the human life sciences sector. The company targets opportunities in biotechnology, early-stage and revenue-stage opportunities in medical devices, and growth equity investments for later-stage businesses in healthcare services and digital health. It was founded in 1993 and is based in London, U.K.
Latest SV Health Investors News
Feb 14, 2024
Sudo Biosciences, a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced that during January 2024, it completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund (DDF, a SV Health Investors Fund), Leaps by Bayer, and UPMC Enterprises, the innovation, commercialization and venture capital arm of UPMC. This brings the total raised in this upsized round to $147 million. The Series B funding was led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Frazier Life Sciences, Surveyor Capital (a Citadel company), Monograph Capital, Eventide Asset Management, Velosity Capital and new investors DDF, Leaps by Bayer, and UPMC Enterprises. With this second Series B round close, Sudo has raised a total of $188 million since its founding in 2020. Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel medicines to transform patients' lives. The company's programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions. The company's pipeline of next generation TYK2 inhibitors includes a potential first- and best-in-class brain-penetrant candidate for the treatment of multiple sclerosis and neurodegenerative diseases with underlying neuroinflammation and a potential first- and best-in-class topical candidate for immune-mediated dermatologic diseases. Both candidates are anticipated to enter clinical trials in 2024. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
SV Health Investors Frequently Asked Questions (FAQ)
When was SV Health Investors founded?
SV Health Investors was founded in 1993.
Where is SV Health Investors's headquarters?
SV Health Investors's headquarters is located at 71 Kingsway, London.
Who are SV Health Investors's competitors?
Competitors of SV Health Investors include StemPoint Capital and 4 more.
Compare SV Health Investors to Competitors
Sciety is an investment syndicate that offers capital market services with a focus on life science. It specializes in investment, finance, market analysis, and more. It is based in Stockholm, Sweden.
Abingworth is an international investment group focused exclusively on the life sciences and healthcare sectors. It was founded in 1973 and is based in London, United Kingdom.
Gershon Capital is an evergreen Swiss healthcare venture fund and hedge fund. It provides capital and strategic guidance for emerging life science companies with strong commercial potential in biotechnology, medical devices, healthcare AI, wearable sensors, and health and wellness. The company was founded in 2009 and is based in Switzerland.
Syncona Partners (LON: SYNC) is an investment company. The company offers services that include founding, building, and funding companies. It makes investments in life sciences companies including gene therapy, cell therapy, biologics, and small molecule fields. The company was founded in 2012 and is based in London, U.K.
Medilink UK is a not-for-profit association focused on supporting the health technology and life sciences sectors. The company offers professional consultancy and membership services aimed at fostering innovation and improving patient care by connecting the NHS, industry, and academia. Medilink UK primarily serves the life sciences industry, including medical devices, diagnostics, drug delivery, and digital health sectors. It was founded in 2005 and is based in Nottingham, England.
StemPoint Capital is an equity asset management firm dedicated to the global life sciences industry. It offers seeks to leverage growth aspects of the biotechnology sector and the defensive qualities of the pharmaceutical industry to potentially generate absolute returns in varying market cycles. StemPoint Capital was founded in 2023 and is based in New York, New York.